Search

Your search keyword '"Estcourt, Lise J."' showing total 339 results
Start Over Author "Estcourt, Lise J."
339 results on '"Estcourt, Lise J."'

1. Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee surgery: a systematic review and network meta-analysis

Author

Gibbs, Victoria N, additional, Champaneria, Rita, additional, Sandercock, Josie, additional, Welton, Nicky J, additional, Geneen, Louise J, additional, Brunskill, Susan J, additional, Dorée, Carolyn, additional, Kimber, Catherine, additional, Palmer, Antony JR, additional, and Estcourt, Lise J, additional

Published
2024
Full Text
View/download PDF

2. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma

Author

Estcourt, Lise J, Cohn, Claudia S, Pagano, Monica B, Iannizzi, Claire, Kreuzberger, Nina, Skoetz, Nicole, Allen, Elizabeth S, Bloch, Evan M, Beaudoin, Gregory, Casadevall, Arturo, Devine, Dana V, Foroutan, Farid, Gniadek, Thomas J, Goel, Ruchika, Gorlin, Jed, Grossman, Brenda J, Joyner, Michael J, Metcalf, Ryan A, Raval, Jay S, Rice, Todd W, Shaz, Beth H, Vassallo, Ralph R, Winters, Jeffrey L, and Tobian, Aaron AR

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, Cancer, Good Health and Well Being, COVID-19, Hospitalization, Humans, Immunization, Passive, SARS-CoV-2, COVID-19 Serotherapy, Medical and Health Sciences, General & Internal Medicine, Clinical sciences
Abstract

DescriptionCoronavirus disease 2019 convalescent plasma (CCP) has emerged as a potential treatment of COVID-19. However, meta-analysis data and recommendations are limited. The Association for the Advancement of Blood and Biotherapies (AABB) developed clinical practice guidelines for the appropriate use of CCP.MethodsThese guidelines are based on 2 living systematic reviews of randomized controlled trials (RCTs) evaluating CCP from 1 January 2019 to 26 January 2022. There were 33 RCTs assessing 21 916 participants. The results were summarized using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) method. An expert panel reviewed the data using the GRADE framework to formulate recommendations.Recommendation 1 (outpatient)The AABB suggests CCP transfusion in addition to the usual standard of care for outpatients with COVID-19 who are at high risk for disease progression (weak recommendation, moderate-certainty evidence).Recommendation 2 (inpatient)The AABB recommends against CCP transfusion for unselected hospitalized persons with moderate or severe disease (strong recommendation, high-certainty evidence). This recommendation does not apply to immunosuppressed patients or those who lack antibodies against SARS-CoV-2.Recommendation 3 (inpatient)The AABB suggests CCP transfusion in addition to the usual standard of care for hospitalized patients with COVID-19 who do not have SARS-CoV-2 antibodies detected at admission (weak recommendation, low-certainty evidence).Recommendation 4 (inpatient)The AABB suggests CCP transfusion in addition to the usual standard of care for hospitalized patients with COVID-19 and preexisting immunosuppression (weak recommendation, low-certainty evidence).Recommendation 5 (prophylaxis)The AABB suggests against prophylactic CCP transfusion for uninfected persons with close contact exposure to a person with COVID-19 (weak recommendation, low-certainty evidence).Good clinical practice statementCCP is most effective when transfused with high neutralizing titers to infected patients early after symptom onset.

Published
2022

4. Convalescent plasma for people with COVID-19: a living systematic review

Author

Iannizzi, Claire, additional, Chai, Khai Li, additional, Piechotta, Vanessa, additional, Valk, Sarah J, additional, Kimber, Catherine, additional, Monsef, Ina, additional, Wood, Erica M, additional, Lamikanra, Abigail A, additional, Roberts, David J, additional, McQuilten, Zoe, additional, So-Osman, Cynthia, additional, Jindal, Aikaj, additional, Cryns, Nora, additional, Estcourt, Lise J, additional, Kreuzberger, Nina, additional, and Skoetz, Nicole, additional

Published
2023
Full Text
View/download PDF

5. Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial

Author

Desmarets, Maxime, primary, Hoffmann, Simone, additional, Vauchy, Charline, additional, Rijnders, Bart J A, additional, Toussirot, Eric, additional, Durrbach, Antoine, additional, Körper, Sixten, additional, Schrezenmeier, Eva, additional, van der Schoot, C Ellen, additional, Harvala, Heli, additional, Brunotte, Gaëlle, additional, Appl, Thomas, additional, Seifried, Erhard, additional, Tiberghien, Pierre, additional, Bradshaw, Daniel, additional, Roberts, David J, additional, Estcourt, Lise J, additional, and Schrezenmeier, Hubert, additional

Published
2023
Full Text
View/download PDF

7. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Author

Goligher, Ewan C, Bradbury, Charlotte A, McVerry, Bryan J, Lawler, Patrick R, Berger, Jeffrey S, Gong, Michelle N, Carrier, Marc, Reynolds, Harmony R, Kumar, Anand, Turgeon, Alexis F, Kornblith, Lucy Z, Kahn, Susan R, Marshall, John C, Kim, Keri S, Houston, Brett L, Derde, Lennie PG, Cushman, Mary, Tritschler, Tobias, Angus, Derek C, Godoy, Lucas C, McQuilten, Zoe, Kirwan, Bridget-Anne, Farkouh, Michael E, Brooks, Maria M, Lewis, Roger J, Berry, Lindsay R, Lorenzi, Elizabeth, Gordon, Anthony C, Ahuja, Tania, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Contreras, Aira, Costantini, Todd W, de Brouwer, Sophie, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Eng, Heather F, Escobedo, Jorge, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Froess, Joshua D, Fu, Zhuxuan, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, Girard, Timothy D, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Haniffa, Rashan, Hegde, Sheila M, Hendrickson, Carolyn M, Higgins, Alisa M, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Huang, David T, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei, King, Andrew J, Knudson, M Margaret, Kornblith, Aaron E, Kutcher, Matthew E, Laffan, Michael A, Lamontagne, Francois, and Le Gal, Grégoire

Subjects
Clinical Trials and Supportive Activities, Clinical Research, Comparative Effectiveness Research, Cardiovascular, Good Health and Well Being, Aged, Anticoagulants, COVID-19, Critical Illness, Female, Hemorrhage, Heparin, Hospital Mortality, Humans, Logistic Models, Male, Middle Aged, Odds Ratio, Respiration, Artificial, Thrombosis, Treatment Failure, COVID-19 Drug Treatment, REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundThrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.MethodsIn an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge.ResultsThe trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio

Published
2021

8. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Author

Lawler, Patrick R, Goligher, Ewan C, Berger, Jeffrey S, Neal, Matthew D, McVerry, Bryan J, Nicolau, Jose C, Gong, Michelle N, Carrier, Marc, Rosenson, Robert S, Reynolds, Harmony R, Turgeon, Alexis F, Escobedo, Jorge, Huang, David T, Bradbury, Charlotte A, Houston, Brett L, Kornblith, Lucy Z, Kumar, Anand, Kahn, Susan R, Cushman, Mary, McQuilten, Zoe, Slutsky, Arthur S, Kim, Keri S, Gordon, Anthony C, Kirwan, Bridget-Anne, Brooks, Maria M, Higgins, Alisa M, Lewis, Roger J, Lorenzi, Elizabeth, Berry, Scott M, Berry, Lindsay R, Aday, Aaron W, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Costantini, Todd W, de Brouwer, Sophie, Derde, Lennie PG, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, García-Madrona, Sebastian, Girard, Timothy D, Godoy, Lucas C, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Hamburg, Naomi M, Haniffa, Rashan, Hanna, George, Hanna, Nicholas, Hegde, Sheila M, Hendrickson, Carolyn M, Hite, R Duncan, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Iyer, Vivek N, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei L, King, Andrew J, Knudson, M Margaret, Kornblith, Aaron E, and Krishnan, Vidya

Subjects
Cardiovascular, Clinical Trials and Supportive Activities, Clinical Research, Hematology, Transplantation, Good Health and Well Being, Adult, Aged, Anticoagulants, COVID-19, Female, Hemorrhage, Heparin, Heparin, Low-Molecular-Weight, Hospital Mortality, Humans, Male, Middle Aged, Survival Analysis, Thrombosis, COVID-19 Drug Treatment, ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundThrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.MethodsIn this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level.ResultsThe trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis.ConclusionsIn noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT04359277, and NCT02735707.).

Published
2021

9. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.

Author

REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher, Ewan C, Bradbury, Charlotte A, McVerry, Bryan J, Lawler, Patrick R, Berger, Jeffrey S, Gong, Michelle N, Carrier, Marc, Reynolds, Harmony R, Kumar, Anand, Turgeon, Alexis F, Kornblith, Lucy Z, Kahn, Susan R, Marshall, John C, Kim, Keri S, Houston, Brett L, Derde, Lennie PG, Cushman, Mary, Tritschler, Tobias, Angus, Derek C, Godoy, Lucas C, McQuilten, Zoe, Kirwan, Bridget-Anne, Farkouh, Michael E, Brooks, Maria M, Lewis, Roger J, Berry, Lindsay R, Lorenzi, Elizabeth, Gordon, Anthony C, Ahuja, Tania, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Contreras, Aira, Costantini, Todd W, de Brouwer, Sophie, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Eng, Heather F, Escobedo, Jorge, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Froess, Joshua D, Fu, Zhuxuan, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, Girard, Timothy D, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Haniffa, Rashan, Hegde, Sheila M, Hendrickson, Carolyn M, Higgins, Alisa M, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Huang, David T, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei, King, Andrew J, Knudson, M Margaret, Kornblith, Aaron E, and Kutcher, Matthew E

Subjects
REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Humans, Thrombosis, Critical Illness, Hemorrhage, Heparin, Anticoagulants, Treatment Failure, Respiration, Artificial, Hospital Mortality, Logistic Models, Odds Ratio, Aged, Middle Aged, Female, Male, COVID-19, Clinical Research, Cardiovascular, Clinical Trials and Supportive Activities, Comparative Effectiveness Research, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundThrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.MethodsIn an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge.ResultsThe trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio

Published
2021

10. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.

Author

ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, Patrick R, Goligher, Ewan C, Berger, Jeffrey S, Neal, Matthew D, McVerry, Bryan J, Nicolau, Jose C, Gong, Michelle N, Carrier, Marc, Rosenson, Robert S, Reynolds, Harmony R, Turgeon, Alexis F, Escobedo, Jorge, Huang, David T, Bradbury, Charlotte A, Houston, Brett L, Kornblith, Lucy Z, Kumar, Anand, Kahn, Susan R, Cushman, Mary, McQuilten, Zoe, Slutsky, Arthur S, Kim, Keri S, Gordon, Anthony C, Kirwan, Bridget-Anne, Brooks, Maria M, Higgins, Alisa M, Lewis, Roger J, Lorenzi, Elizabeth, Berry, Scott M, Berry, Lindsay R, Aday, Aaron W, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Costantini, Todd W, de Brouwer, Sophie, Derde, Lennie PG, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, García-Madrona, Sebastian, Girard, Timothy D, Godoy, Lucas C, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Hamburg, Naomi M, Haniffa, Rashan, Hanna, George, Hanna, Nicholas, Hegde, Sheila M, Hendrickson, Carolyn M, Hite, R Duncan, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Iyer, Vivek N, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei L, and King, Andrew J

Subjects
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Humans, Thrombosis, Hemorrhage, Heparin, Heparin, Low-Molecular-Weight, Anticoagulants, Hospital Mortality, Survival Analysis, Adult, Aged, Middle Aged, Female, Male, COVID-19, Hematology, Clinical Trials and Supportive Activities, Transplantation, Clinical Research, Cardiovascular, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundThrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.MethodsIn this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level.ResultsThe trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis.ConclusionsIn noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT04359277, and NCT02735707.).

Published
2021

11. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Author

Arabi, Yaseen M, Gordon, Anthony C, Derde, Lennie PG, Nichol, Alistair D, Murthy, Srinivas, Beidh, Farah Al, Annane, Djillali, Swaidan, Lolowa Al, Beane, Abi, Beasley, Richard, Berry, Lindsay R, Bhimani, Zahra, Bonten, Marc JM, Bradbury, Charlotte A, Brunkhorst, Frank M, Buxton, Meredith, Buzgau, Adrian, Cheng, Allen, De Jong, Menno, Detry, Michelle A, Duffy, Eamon J, Estcourt, Lise J, Fitzgerald, Mark, Fowler, Rob, Girard, Timothy D, Goligher, Ewan C, Goossens, Herman, Haniffa, Rashan, Higgins, Alisa M, Hills, Thomas E, Horvat, Christopher M, Huang, David T, King, Andrew J, Lamontagne, Francois, Lawler, Patrick R, Lewis, Roger, Linstrum, Kelsey, Litton, Edward, Lorenzi, Elizabeth, Malakouti, Salim, McAuley, Daniel F, McGlothlin, Anna, Mcguinness, Shay, McVerry, Bryan J, Montgomery, Stephanie K, Morpeth, Susan C, Mouncey, Paul R, Orr, Katrina, Parke, Rachael, Parker, Jane C, Patanwala, Asad E, Rowan, Kathryn M, Santos, Marlene S, Saunders, Christina T, Seymour, Christopher W, Shankar-Hari, Manu, Tong, Steven YC, Turgeon, Alexis F, Turner, Anne M, Van de Veerdonk, Frank Leo, Zarychanski, Ryan, Green, Cameron, Berry, Scott, Marshall, John C, McArthur, Colin, Angus, Derek C, and Webb, Steven A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Comparative Effectiveness Research, Clinical Research, Clinical Trials and Supportive Activities, Good Health and Well Being, Adult, Antiviral Agents, Bayes Theorem, Critical Illness, Drug Combinations, Humans, Hydroxychloroquine, Lopinavir, Ritonavir, SARS-CoV-2, COVID-19 Drug Treatment, Adaptive platform trial, Intensive care, Pneumonia, Pandemic, COVID-19, Lopinavir-ritonavir, REMAP-CAP Investigators, Public Health and Health Services, Emergency & Critical Care Medicine, Clinical sciences
Abstract

PurposeTo study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill patients with coronavirus disease 2019 (COVID-19).MethodsCritically ill adults with COVID-19 were randomized to receive lopinavir-ritonavir, hydroxychloroquine, combination therapy of lopinavir-ritonavir and hydroxychloroquine or no antiviral therapy (control). The primary endpoint was an ordinal scale of organ support-free days. Analyses used a Bayesian cumulative logistic model and expressed treatment effects as an adjusted odds ratio (OR) where an OR > 1 is favorable.ResultsWe randomized 694 patients to receive lopinavir-ritonavir (n = 255), hydroxychloroquine (n = 50), combination therapy (n = 27) or control (n = 362). The median organ support-free days among patients in lopinavir-ritonavir, hydroxychloroquine, and combination therapy groups was 4 (- 1 to 15), 0 (- 1 to 9) and-1 (- 1 to 7), respectively, compared to 6 (- 1 to 16) in the control group with in-hospital mortality of 88/249 (35%), 17/49 (35%), 13/26 (50%), respectively, compared to 106/353 (30%) in the control group. The three interventions decreased organ support-free days compared to control (OR [95% credible interval]: 0.73 [0.55, 0.99], 0.57 [0.35, 0.83] 0.41 [0.24, 0.72]), yielding posterior probabilities that reached the threshold futility (≥ 99.0%), and high probabilities of harm (98.0%, 99.9% and > 99.9%, respectively). The three interventions reduced hospital survival compared with control (OR [95% CrI]: 0.65 [0.45, 0.95], 0.56 [0.30, 0.89], and 0.36 [0.17, 0.73]), yielding high probabilities of harm (98.5% and 99.4% and 99.8%, respectively).ConclusionAmong critically ill patients with COVID-19, lopinavir-ritonavir, hydroxychloroquine, or combination therapy worsened outcomes compared to no antiviral therapy.

Published
2021

13. Hyperimmune immunoglobulin for people with COVID-19

Author

Kimber, Catherine, additional, Valk, Sarah J, additional, Chai, Khai Li, additional, Piechotta, Vanessa, additional, Iannizzi, Claire, additional, Monsef, Ina, additional, Wood, Erica M, additional, Lamikanra, Abigail A, additional, Roberts, David J, additional, McQuilten, Zoe, additional, So-Osman, Cynthia, additional, Estcourt, Lise J, additional, and Skoetz, Nicole, additional

Published
2023
Full Text
View/download PDF

16. Pharmacological interventions for the treatment of bleeding in people treated for blunt force or penetrating injury in an emergency department: a systematic review and network meta-analysis

Author

Erasu, Vishakha, additional, Novak, Alex, additional, Gibbs, Victoria N, additional, Champaneria, Rita, additional, Dorée, Carolyn, additional, Hafeez, Aqib, additional, Moy, Ross, additional, Sandercock, Josie, additional, Brunskill, Susan J, additional, and Estcourt, Lise J, additional

Published
2022
Full Text
View/download PDF

17. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19

Author

Hirsch, Caroline, additional, Park, Yun Soo, additional, Piechotta, Vanessa, additional, Chai, Khai Li, additional, Estcourt, Lise J, additional, Monsef, Ina, additional, Salomon, Susanne, additional, Wood, Erica M, additional, So-Osman, Cynthia, additional, McQuilten, Zoe, additional, Spinner, Christoph D, additional, Malin, Jakob J, additional, Stegemann, Miriam, additional, Skoetz, Nicole, additional, and Kreuzberger, Nina, additional

Published
2022
Full Text
View/download PDF

19. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial

Author

Bradbury, Charlotte A., Lawler, Patrick R., Stanworth, Simon J., McVerry, Bryan J., McQuilten, Zoe, Higgins, Alisa M., Mouncey, Paul R., Beidh, Farah al-, Rowan, Kathryn M., Berry, Lindsay R., Lorenzi, Elizabeth, Zarychanski, Ryan, Arabi, Yaseen M., Annane, Djillali, Beane, Abi, Bentum-Puijk, Wilma van, Bhimani, Zahra, Bihari, Shailesh, Bonten, Marc J.M., Brunkhorst, Frank M., Buzgau, Adrian, Buxton, Meredith, Carrier, Marc, Cheng, Allen C., Cove, Matthew, Detry, Michelle A., Estcourt, Lise J., Fitzgerald, Mark, Girard, Timothy D., Goligher, Ewan C., Goossens, Herman, Haniffa, Rashan, Hills, Thomas, Huang, David T., Horvat, Christopher M., Hunt, Beverley J., Ichihara, Nao, Lamontagne, Francois, Leavis, Helen L., Linstrum, Kelsey M., Litton, Edward, Marshall, John C., McAuley, Daniel F., McGlothlin, Anna, McGuinness, Shay P., Middeldorp, Saskia, Montgomery, Stephanie K., Morpeth, Susan C., Murthy, Srinivas, Neal, Matthew D., Nichol, Alistair D., Parke, Rachael L., Parker, Jane C., Reyes, Luis F., Saito, Hiroki, Santos, Marlene S., Saunders, Christina T., Serpa-Neto, Ary, Seymour, Christopher W., Shankar-Hari, Manu, Singh, Vanessa, Tolppa, Timo, Turgeon, Alexis F., Turner, Anne M., Veerdonk, Frank L. van de, Green, Cameron, Lewis, Roger J., Angus, Derek C., McArthur, Colin J., Berry, Scott, Derde, Lennie P.G., Webb, Steve A., and Gordon, Anthony C.

Subjects
Critically ill -- Care and treatment, Blood platelets -- Aggregation, Health
Published
2022

25. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial

Author

Estcourt, Lise J., Turgeon, Alexis F., McQuilten, Zoe K., McVerry, Bryan J., Beidh, Farah al-, Annane, Djillali, Arabi, Yaseen M., Arnold, Donald M., Beane, Abigail, Begin, Philippe, Bentum-Puijk, Wilma van, Berry, Lindsay R., Bhimani, Zahra, Birchall, Janet E., Bonten, Marc J.M., Bradbury, Charlotte A., Brunkhorst, Frank M., Buxton, Meredith, Callum, Jeannie L., Chasse, Michael, Cheng, Allen C., Cove, Matthew E., Daly, James, Derde, Lennie, Detry, Michelle A., De Jong, Menno, Evans, Amy, Fergusson, Dean A., Fish, Matthew, Fitzgerald, Mark, Foley, Claire, Goossens, Herman, Gordon, Anthony C., Gosbell, Iain B., Green, Cameron, Haniffa, Rashan, Harvala, Heli, Higgins, Alisa M., Hills, Thomas E., Hoad, Veronica C., Horvat, Christopher, Huang, David T., Hudson, Cara L., Ichihara, Nao, Laing, Emma, Lamikanra, Abigail A., Lamontagne, Francois, Lawler, Patrick R., Linstrum, Kelsey, Litton, Edward, Lorenzi, Elizabeth, MacLennan, Sheila, Marshall, John, McAuley, Daniel F., McDyer, John F., McGlothlin, Anna, McGuinness, Shay, Miflin, Gail, Montgomery, Stephanie, Mouncey, Paul R., Murthy, Srinivas, Nichol, Alistair, Parke, Rachael, Parker, Jane C., Priddee, Nicole, Purcell, Damian F.J., Reyes, Luis F., Richardson, Peter, Robitaille, Nancy, Rowan, Kathryn M., Rynne, Jennifer, Saito, Hiroki, Santos, Marlene, Saunders, Christina T., Neto, Ary Serpa, Seymour, Christopher W., Silversides, Jon A., Tinmouth, Alan A., Triulzi, Darrell J., Turner, Anne M., Veerdonk, Frank van de, Walsh, Timothy S., Wood, Erica M., Berry, Scott, Lewis, Roger J., Menon, David K., McArthur, Colin, Zarychanski, Ryan, Angus, Derek C., Webb, Steve A., Roberts, David J., and Shankar-Hari, Manu

Subjects
Critically ill -- Care and treatment, Health
Published
2021

27. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Author

Axfors, Cathrine, primary, Janiaud, Perrine, additional, Schmitt, Andreas M., additional, van’t Hooft, Janneke, additional, Smith, Emily R., additional, Haber, Noah A., additional, Abayomi, Akin, additional, Abduljalil, Manal, additional, Abdulrahman, Abdulkarim, additional, Acosta-Ampudia, Yeny, additional, Aguilar-Guisado, Manuela, additional, Al-Beidh, Farah, additional, Alejandria, Marissa M., additional, Alfonso, Rachelle N., additional, Ali, Mohammad, additional, AlQahtani, Manaf, additional, AlZamrooni, Alaa, additional, Anaya, Juan-Manuel, additional, Ang, Mark Angelo C., additional, Aomar, Ismael F., additional, Argumanis, Luis E., additional, Averyanov, Alexander, additional, Baklaushev, Vladimir P., additional, Balionis, Olga, additional, Benfield, Thomas, additional, Berry, Scott, additional, Birocco, Nadia, additional, Bonifacio, Lynn B., additional, Bowen, Asha C., additional, Bown, Abbie, additional, Cabello-Gutierrez, Carlos, additional, Camacho, Bernardo, additional, Camacho-Ortiz, Adrian, additional, Campbell-Lee, Sally, additional, Cao, Damon H., additional, Cardesa, Ana, additional, Carnate, Jose M., additional, Castillo, German Jr. J., additional, Cavallo, Rossana, additional, Chowdhury, Fazle R., additional, Chowdhury, Forhad U. H., additional, Ciccone, Giovannino, additional, Cingolani, Antonella, additional, Climacosa, Fresthel Monica M., additional, Compernolle, Veerle, additional, Cortez, Carlo Francisco N., additional, Costa Neto, Abel, additional, D’Antico, Sergio, additional, Daly, James, additional, Danielle, Franca, additional, Davis, Joshua S., additional, De Rosa, Francesco Giuseppe, additional, Denholm, Justin T., additional, Denkinger, Claudia M., additional, Desmecht, Daniel, additional, Díaz-Coronado, Juan C., additional, Díaz Ponce-Medrano, Juan A., additional, Donneau, Anne-Françoise, additional, Dumagay, Teresita E., additional, Dunachie, Susanna, additional, Dungog, Cecile C., additional, Erinoso, Olufemi, additional, Escasa, Ivy Mae S., additional, Estcourt, Lise J., additional, Evans, Amy, additional, Evasan, Agnes L. M., additional, Fareli, Christian J., additional, Fernandez-Sanchez, Veronica, additional, Galassi, Claudia, additional, Gallo, Juan E., additional, Garcia, Patricia J., additional, Garcia, Patricia L., additional, Garcia, Jesus A., additional, Garigliany, Mutien, additional, Garza-Gonzalez, Elvira, additional, Gauiran, Deonne Thaddeus V., additional, Gaviria García, Paula A., additional, Giron-Gonzalez, Jose-Antonio, additional, Gómez-Almaguer, David, additional, Gordon, Anthony C., additional, Gothot, André, additional, Grass Guaqueta, Jeser Santiago, additional, Green, Cameron, additional, Grimaldi, David, additional, Hammond, Naomi E., additional, Harvala, Heli, additional, Heralde, Francisco M., additional, Herrick, Jesica, additional, Higgins, Alisa M., additional, Hills, Thomas E., additional, Hines, Jennifer, additional, Holm, Karin, additional, Hoque, Ashraful, additional, Hoste, Eric, additional, Ignacio, Jose M., additional, Ivanov, Alexander V., additional, Janssen, Maike, additional, Jennings, Jeffrey H., additional, Jha, Vivekanand, additional, King, Ruby Anne N., additional, Kjeldsen-Kragh, Jens, additional, Klenerman, Paul, additional, Kotecha, Aditya, additional, Krapp, Fiorella, additional, Labanca, Luciana, additional, Laing, Emma, additional, Landin-Olsson, Mona, additional, Laterre, Pierre-François, additional, Lim, Lyn-Li, additional, Lim, Jodor, additional, Ljungquist, Oskar, additional, Llaca-Díaz, Jorge M., additional, López-Robles, Concepción, additional, López-Cárdenas, Salvador, additional, Lopez-Plaza, Ileana, additional, Lucero, Josephine Anne C., additional, Lundgren, Maria, additional, Macías, Juan, additional, Maganito, Sandy C., additional, Malundo, Anna Flor G., additional, Manrique, Rubén D., additional, Manzini, Paola M., additional, Marcos, Miguel, additional, Marquez, Ignacio, additional, Martínez-Marcos, Francisco Javier, additional, Mata, Ana M., additional, McArthur, Colin J., additional, McQuilten, Zoe K., additional, McVerry, Bryan J., additional, Menon, David K., additional, Meyfroidt, Geert, additional, Mirasol, Ma. Angelina L., additional, Misset, Benoît, additional, Molton, James S., additional, Mondragon, Alric V., additional, Monsalve, Diana M., additional, Moradi Choghakabodi, Parastoo, additional, Morpeth, Susan C., additional, Mouncey, Paul R., additional, Moutschen, Michel, additional, Müller-Tidow, Carsten, additional, Murphy, Erin, additional, Najdovski, Tome, additional, Nichol, Alistair D., additional, Nielsen, Henrik, additional, Novak, Richard M., additional, O’Sullivan, Matthew V. N., additional, Olalla, Julian, additional, Osibogun, Akin, additional, Osikomaiya, Bodunrin, additional, Oyonarte, Salvador, additional, Pardo-Oviedo, Juan M., additional, Patel, Mahesh C., additional, Paterson, David L., additional, Peña-Perez, Carlos A., additional, Perez-Calatayud, Angel A., additional, Pérez-Alba, Eduardo, additional, Perkina, Anastasia, additional, Perry, Naomi, additional, Pouladzadeh, Mandana, additional, Poyato, Inmaculada, additional, Price, David J., additional, Quero, Anne Kristine H., additional, Rahman, Md. M., additional, Rahman, Md. S., additional, Ramesh, Mayur, additional, Ramírez-Santana, Carolina, additional, Rasmussen, Magnus, additional, Rees, Megan A., additional, Rego, Eduardo, additional, Roberts, Jason A., additional, Roberts, David J., additional, Rodríguez, Yhojan, additional, Rodríguez-Baño, Jesús, additional, Rogers, Benjamin A., additional, Rojas, Manuel, additional, Romero, Alberto, additional, Rowan, Kathryn M., additional, Saccona, Fabio, additional, Safdarian, Mehdi, additional, Santos, Maria Clariza M., additional, Sasadeusz, Joe, additional, Scozzari, Gitana, additional, Shankar-Hari, Manu, additional, Sharma, Gorav, additional, Snelling, Thomas, additional, Soto, Alonso, additional, Tagayuna, Pedrito Y., additional, Tang, Amy, additional, Tatem, Geneva, additional, Teofili, Luciana, additional, Tong, Steven Y. C., additional, Turgeon, Alexis F., additional, Veloso, Januario D., additional, Venkatesh, Balasubramanian, additional, Ventura-Enriquez, Yanet, additional, Webb, Steve A., additional, Wiese, Lothar, additional, Wikén, Christian, additional, Wood, Erica M., additional, Yusubalieva, Gaukhar M., additional, Zacharowski, Kai, additional, Zarychanski, Ryan, additional, Khanna, Nina, additional, Moher, David, additional, Goodman, Steven N., additional, Ioannidis, John P. A., additional, and Hemkens, Lars G., additional

Published
2021
Full Text
View/download PDF

28. Hyperimmune immunoglobulin for people with COVID-19

Author

Kimber, Catherine, additional, Valk, Sarah J, additional, Chai, Khai Li, additional, Piechotta, Vanessa, additional, Iannizzi, Claire, additional, Monsef, Ina, additional, Wood, Erica M, additional, Lamikanra, Abigail A, additional, Roberts, David J, additional, McQuilten, Zoe, additional, So-Osman, Cynthia, additional, Estcourt, Lise J, additional, and Skoetz, Nicole, additional

Published
2021
Full Text
View/download PDF

30. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Author

Kreuzberger, Nina, additional, Hirsch, Caroline, additional, Chai, Khai Li, additional, Tomlinson, Eve, additional, Khosravi, Zahra, additional, Popp, Maria, additional, Neidhardt, Miriam, additional, Piechotta, Vanessa, additional, Salomon, Susanne, additional, Valk, Sarah J, additional, Monsef, Ina, additional, Schmaderer, Christoph, additional, Wood, Erica M, additional, So-Osman, Cynthia, additional, Roberts, David J, additional, McQuilten, Zoe, additional, Estcourt, Lise J, additional, and Skoetz, Nicole, additional

Published
2021
Full Text
View/download PDF

31. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Author

Gordon, Anthony C., Mouncey, Raul R., Beidh, Farah al-, Rowan, Kathryn M., Nichol, Alistair D., Arabi, Yaseen M., Annane, Djillali, Beane,Abi, Bentum-Puijk, Wilma van, Berry, Lindsay R., Bhimani, Zahra, Bonten, Marc J.M., Bradbury, Charlotte A., Brunkhorst, Frank M., Buzgau, Adrian, Cheng, Allen C., Detry, Michelle A., Duffy, Eamon J., Estcourt, Lise J., Fitzgerald, Mark, Goosens,Herman, Haniffa, Rashan, Higgins, Alisa M., Hills, Thomas E., Horvat, Christopher M., Lamontagne, Francois, Lawler, Patrick R., Leavis, Helen L., Linstrum, Kelsey M., Litton, Edward, Lorenzi, Elizabeth, Marshall, John C., Mayr, Florian B., McAuley, Daniel F., McGlothlin, Anna, McGuinness, Shay P., McVerry, Bryan J., Montgomery, Stephanie K., Morpeth, Susan C., Murthy, Srinivas, Orr, Katrina, Parke, Rachael L., Parker, Jane C., Patanwala, Asad E., Pettila, Ville, Rademaker, Emma, Santos, Marlene S., Saunders, Christina T., Seymour, Christopher W., Shankar-Hari, Manu, Sligl, Wendy I., Turgeon, Alexis F., Turner, Anne M., Veerdonk, Frank L. van de, Zarychanski, Ryan, Green, Cameron, Lewis, Roger J., Angus, Derek C., McArthur, Colin J., Berry, Scott, Webb, Steve A., and Derde, Lennie P.G.

Subjects
Drug therapy, Usage, Sarilumab -- Usage, Tocilizumab -- Usage, COVID-19 -- Drug therapy
Published
2021

32. Clinical decision support versus a paper‐based protocol for massive transfusion: Impact on decision outcomes in a simulation study.

Author

Sanderson, Brenton J., Field, Jeremy D., Kocaballi, Ahmet B., Estcourt, Lise J., Magrabi, Farah, Wood, Erica M., and Coiera, Enrico

Subjects
CLINICAL decision support systems, COGNITIVE load, MEDICAL simulation
Abstract

Background: Management of major hemorrhage frequently requires massive transfusion (MT) support, which should be delivered effectively and efficiently. We have previously developed a clinical decision support system (CDS) for MT using a multicenter multidisciplinary user‐centered design study. Here we examine its impact when administering a MT. Study Design and Methods: We conducted a randomized simulation trial to compare a CDS for MT with a paper‐based MT protocol for the management of simulated hemorrhage. A total of 44 specialist physicians, trainees (residents), and nurses were recruited across critical care to participate in two 20‐min simulated bleeding scenarios. The primary outcome was the decision velocity (correct decisions per hour) and overall task completion. Secondary outcomes included cognitive workload and System Usability Scale (SUS). Results: There was a statistically significant increase in decision velocity for CDS‐based management (mean 8.5 decisions per hour) compared to paper based (mean 6.9 decisions per hour; p.003, 95% CI 0.6–2.6). There was no significant difference in the overall task completion using CDS‐based management (mean 13.3) compared to paper‐based (mean 13.2; p.92, 95% CI ‐1.2–1.3). Cognitive workload was statistically significantly lower using the CDS compared to the paper protocol (mean 57.1 vs. mean 64.5, p.005, 95% CI 2.4–12.5). CDS usability was assessed as a SUS score of 82.5 (IQR 75–87.5). Discussion: Compared to paper‐based management, CDS‐based MT supports more time‐efficient decision‐making by users with limited CDS training and achieves similar overall task completion while reducing cognitive load. Clinical implementation will determine whether the benefits demonstrated translate to improved patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Author

Piechotta, Vanessa, additional, Iannizzi, Claire, additional, Chai, Khai Li, additional, Valk, Sarah J, additional, Kimber, Catherine, additional, Dorando, Elena, additional, Monsef, Ina, additional, Wood, Erica M, additional, Lamikanra, Abigail A, additional, Roberts, David J, additional, McQuilten, Zoe, additional, So-Osman, Cynthia, additional, Estcourt, Lise J, additional, and Skoetz, Nicole, additional

Published
2021
Full Text
View/download PDF

34. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19

Author

Hirsch, Caroline, additional, Valk, Sarah J, additional, Piechotta, Vanessa, additional, Chai, Khai Li, additional, Estcourt, Lise J, additional, Monsef, Ina, additional, Salomon, Susanne, additional, Tomlinson, Eve, additional, Popp, Maria, additional, Wood, Erica M, additional, So-Osman, Cynthia, additional, Roberts, David J, additional, McQuilten, Zoe, additional, Skoetz, Nicole, additional, and Kreuzberger, Nina, additional

Published
2021
Full Text
View/download PDF

37. Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS-CoV-2

Author

Valk, Sarah J, additional, Piechotta, Vanessa, additional, Kimber, Catherine, additional, Chai, Khai Li, additional, Monsef, Ina, additional, Doree, Carolyn, additional, Wood, Erica M, additional, Lamikanra, Abigail A, additional, Roberts, David J, additional, McQuilten, Zoe, additional, So-Osman, Cynthia, additional, Estcourt, Lise J, additional, and Skoetz, Nicole, additional

Published
2021
Full Text
View/download PDF

38. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Author

Chai, Khai Li, additional, Valk, Sarah J, additional, Piechotta, Vanessa, additional, Kimber, Catherine, additional, Monsef, Ina, additional, Doree, Carolyn, additional, Wood, Erica M, additional, Lamikanra, Abigail A, additional, Roberts, David J, additional, McQuilten, Zoe, additional, So-Osman, Cynthia, additional, Estcourt, Lise J, additional, and Skoetz, Nicole, additional

Published
2020
Full Text
View/download PDF

40. Clinical use of Convalescent Plasma in the COVID‐19 pandemic: a transfusion‐focussed gap analysis with recommendations for future research priorities

Author

Al‐Riyami, Arwa Z., primary, Schäfer, Richard, additional, Berg, Karin, additional, Bloch, Evan M., additional, Estcourt, Lise J., additional, Goel, Ruchika, additional, Hindawi, Salwa, additional, Josephson, Cassandra D., additional, Land, Kevin, additional, McQuilten, Zoe K., additional, Spitalnik, Steven L., additional, Wood, Erica M., additional, Devine, Dana V., additional, and So‐Osman, Cynthia, additional

Published
2020
Full Text
View/download PDF

42. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis

Author

Kreuzberger, Nina, additional, Damen, Johanna AAG, additional, Trivella, Marialena, additional, Estcourt, Lise J, additional, Aldin, Angela, additional, Umlauff, Lisa, additional, Vazquez-Montes, Maria DLA, additional, Wolff, Robert, additional, Moons, Karel GM, additional, Monsef, Ina, additional, Foroutan, Farid, additional, Kreuzer, Karl-Anton, additional, and Skoetz, Nicole, additional

Published
2020
Full Text
View/download PDF

44. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Author

Piechotta, Vanessa, additional, Chai, Khai Li, additional, Valk, Sarah J, additional, Doree, Carolyn, additional, Monsef, Ina, additional, Wood, Erica M, additional, Lamikanra, Abigail, additional, Kimber, Catherine, additional, McQuilten, Zoe, additional, So-Osman, Cynthia, additional, Estcourt, Lise J, additional, and Skoetz, Nicole, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results